Gentian Diagnostics ASA
ISIN: NO0010748866 | Ticker: GENT | LEI: 5967007LIEEXZXHNM861
Country: Norway
Gentian is a Norwegian IVD company that specialises in developing and manufacturing turbidimetric assays that enable clinical lab professionals to achieve greater operational efficiency, thus providing faster patient results to clinicians. The current portfolio and pipeline of diagnostic reagents span areas of kidney disease, cardiac disease, inflammation, infection and veterinary medicine.
By leveraging both our expertise in Particle-Enhanced Turbidimetric Immunoassays (PETIA) and proprietary nanoparticle technology, we develop immunoassays that enable users to transition from traditional low volume immunology platforms to fully automated clinical chemistry instruments. The typical Gentian customer enjoys shorter turnaround times, streamlined workflows and improved cost efficiency.
2001
Served areaWorldwide
HeadquartersPB 733, 1509 Moss – Norway
| Line item in (nok) | 01.01.2020 | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|---|
| Assets | N/A | 235,265,000.00 | 211,790,000.00 | 187,790,000.00 |
| Noncurrent Assets | N/A | 41,164,000.00 | 44,495,000.00 | 48,458,000.00 |
| Property Plant And Equipment | N/A | 3,865,000.00 | 3,363,000.00 | 9,251,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 15,610,000.00 | 25,006,000.00 | 26,820,000.00 |
| Current Assets | N/A | 194,102,000.00 | 167,295,000.00 | 139,332,000.00 |
| Trade And Other Current Receivables | N/A | 15,241,000.00 | 22,580,000.00 | 19,188,000.00 |
| Cash and cash equivalents | N/A | 157,985,000.00 | 114,936,000.00 | 81,599,000.00 |
| Equity And Liabilities | N/A | 235,265,000.00 | 211,790,000.00 | 187,790,000.00 |
| Equity | 208,240,000.00 | 194,579,000.00 | 174,766,000.00 | 154,170,000.00 |
| Issued Capital | N/A | 1,541,000.00 | 1,542,000.00 | 1,542,000.00 |
| Retained Earnings | N/A | -107,512,000.00 | -132,528,000.00 | -156,477,000.00 |
| Share Premium | N/A | 293,241,000.00 | 293,810,000.00 | 293,810,000.00 |
| Additional Paidin Capital | N/A | 7,309,000.00 | 11,941,000.00 | 15,294,000.00 |
| Liabilities | N/A | 40,686,000.00 | 37,024,000.00 | 33,620,000.00 |
| Noncurrent Liabilities | N/A | 18,101,000.00 | 14,470,000.00 | 11,624,000.00 |
| Current Liabilities | N/A | 22,585,000.00 | 22,554,000.00 | 21,996,000.00 |
| Current Payables On Social Security And Taxes Other Than Income Tax | N/A | 3,127,000.00 | 3,598,000.00 | 4,965,000.00 |
| Other Current Liabilities | N/A | 9,476,000.00 | 9,868,000.00 | 8,889,000.00 |
| Line item in (nok) | 01.01.2020/ 01.01.2021 |
01.01.2021/ 01.01.2022 |
01.01.2022/ 01.01.2023 |
|---|---|---|---|
| Revenue From Contracts With Customers | 63,327,000.00 | 83,122,000.00 | 101,636,000.00 |
| Other Income | 15,554,000.00 | 16,887,000.00 | 10,287,000.00 |
| Cost Of Merchandise Sold | 32,586,000.00 | 43,176,000.00 | 52,635,000.00 |
| Employee Benefits Expense | 37,231,000.00 | 39,539,000.00 | 40,910,000.00 |
| Depreciation And Amortisation Expense | 6,630,000.00 | 7,351,000.00 | 10,243,000.00 |
| Profit Loss From Operating Activities | -17,824,000.00 | -22,847,000.00 | -23,235,000.00 |
| Finance Income | 1,840,000.00 | 2,084,000.00 | 3,831,000.00 |
| Finance Costs | 1,484,000.00 | 4,031,000.00 | 4,213,000.00 |
| Profit Loss Before Tax | -17,469,000.00 | -24,794,000.00 | -23,618,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 | 0.00 |
| Profit (loss) | -17,469,000.00 | -24,794,000.00 | -23,618,000.00 |
| Line item in (nok) | 01.01.2021 | 01.01.2022 | 01.01.2023 |
|---|---|---|---|
| Profit (loss) | -17,469,000.00 | -24,794,000.00 | -23,618,000.00 |
| Adjustments For Decrease Increase In Inventories | 2,652,000.00 | 8,904,000.00 | 8,765,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | 1,202,000.00 | -833,000.00 | -532,000.00 |
| Adjustments For Sharebased Payments | 3,278,000.00 | 4,633,000.00 | N/A |
| Cash Flows From Used In Operating Activities | -12,509,000.00 | -27,053,000.00 | -13,952,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | 2,734,000.00 | 1,024,000.00 | 8,637,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | 3,733,000.00 | 11,791,000.00 | 6,029,000.00 |
| Cash Flows From Used In Investing Activities | 274,000.00 | -12,815,000.00 | -14,666,000.00 |
| Proceeds From Issuing Shares | 462,000.00 | 570,000.00 | 0.00 |
| Proceeds From Borrowings Classified As Financing Activities | 497,000.00 | 0.00 | 0.00 |
| Repayments Of Borrowings Classified As Financing Activities | 2,469,000.00 | 3,691,000.00 | 4,325,000.00 |
| Cash Flows From Used In Financing Activities | -1,510,000.00 | -3,121,000.00 | -4,325,000.00 |
| Increase (decrease) in cash and cash equivalents before effect of exchange rate changes | -13,745,000.00 | -42,989,000.00 | -32,943,000.00 |
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | 163,000.00 | -60,000.00 | -395,000.00 |
| Cash and cash equivalents | 157,985,000.00 | 114,936,000.00 | 81,599,000.00 |
Please note that some sums might not add up.
NO0010748866
LEI5967007LIEEXZXHNM861
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.